Praxis Precision Medicines, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Praxis Precision Medicines, Inc. | PRAX - NASDAQ |
$17.00-$18.00 | $19.00 | $25.94 | 10 million | 10/16/2020 |
| Cowen, Evercore ISI, Piper Sandler | ||||||
Co-Manager(s): Wedbush PacGrow, Blackstone Capital | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-09-25 Terms Added 2020-10-09 Amended Terms 2020-10-15 | ||||||
Praxis Precision Medicines, Inc. Quote & Chart - Click for current quote - PRAX
IPO Boutique aggregates information on public companies and private companies, such as "PRAX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Praxis Precision Medicines, Inc. (adapted from Praxis Precision Medicines, Inc. prospectus):
They are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PRAX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.